Viking Therapeutics
VKTX
140 hedge funds and large institutions have $230M invested in Viking Therapeutics in 2020 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 34 increasing their positions, 49 reducing their positions, and 14 closing their positions.
200% more call options, than puts
Call options by funds: $8.28M | Put options by funds: $2.76M
21% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 14
1% more funds holding
Funds holding: 138 → 140 (+2)
1.04% less ownership
Funds ownership: 55.42% → 54.37% (-1%)
21% less capital invested
Capital invested by funds: $290M → $230M (-$60M)
31% less repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 49
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$5.38M |
| 2 |
DM
Deerfield Management
New York
|
+$2.4M |
| 3 |
N
Nuveen
Charlotte,
North Carolina
|
+$1.74M |
| 4 |
SG Americas Securities
New York
|
+$1.61M |
| 5 |
Morgan Stanley
New York
|
+$1.19M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACH
ArrowMark Colorado Holdings
Denver,
Colorado
|
-$3.27M |
| 2 |
Two Sigma Investments
New York
|
-$2.74M |
| 3 |
Millennium Management
New York
|
-$2.52M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$2.07M |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
-$1.92M |
VKTX Hedge Fund Activity: Q3 2020 in Review
140 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Viking Therapeutics (VKTX) for Q3 2020, worth a combined $230M — down 21% from $290M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new VKTX positions and 14 closed out — a net gain of 3 holders — while 34 added to existing stakes and 49 trimmed.
The largest buyer was State Street, adding an estimated $5.38M. The largest seller was ArrowMark Colorado Holdings, cutting an estimated $3.27M.
- 140 institutional investors held Viking Therapeutics (VKTX) as of Q3 2020, up from 138 in Q2 2020.
- Funds reported $230M of Viking Therapeutics stock for Q3 2020, down 21% quarter-over-quarter.
- 17 funds opened new Viking Therapeutics positions in Q3 2020 and 14 closed out, a net change of +3 holders.
- The largest Viking Therapeutics buyer in Q3 2020 was State Street, an estimated $5.38M added.
- The largest Viking Therapeutics seller in Q3 2020 was ArrowMark Colorado Holdings, an estimated $3.27M sold.
Based on aggregated 13F filings for Q3 2020.